Corient Private Wealth LLC boosted its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 24.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,805 shares of the company’s stock after buying an additional 6,751 shares during the quarter. Corient Private Wealth LLC’s holdings in Moderna were worth $1,026,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. MUFG Securities EMEA plc acquired a new stake in shares of Moderna in the second quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new position in Moderna in the 4th quarter valued at $31,000. Ameriflex Group Inc. lifted its holdings in Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after purchasing an additional 1,208 shares in the last quarter. Cromwell Holdings LLC boosted its stake in Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, Director Noubar Afeyan sold 9,263 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the transaction, the director directly owned 3,924 shares in the company, valued at approximately $183,800.16. This represents a 70.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Abbas Hussain sold 5,682 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the completion of the transaction, the director owned 12,066 shares in the company, valued at $562,637.58. This represents a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 125,088 shares of company stock worth $6,193,713. Corporate insiders own 10.80% of the company’s stock.
Analyst Ratings Changes
Moderna Trading Up 10.0%
Shares of MRNA stock opened at $79.76 on Friday. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $81.40. The company’s 50-day moving average price is $53.02 and its 200-day moving average price is $47.87. The stock has a market cap of $31.65 billion, a price-to-earnings ratio of -9.79 and a beta of 0.94.
Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. During the same quarter in the previous year, the business posted ($2.52) earnings per share. Moderna’s revenue for the quarter was up 260.2% on a year-over-year basis. As a group, equities analysts predict that Moderna, Inc. will post -6.51 earnings per share for the current year.
About Moderna
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
See Also
- Five stocks we like better than Moderna
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
